Skip to main content

Table 1 Baseline characteristics of the patients

From: Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report

  

n (%)

Gender

Male

24 (70.6%)

 

Female

10 (29.4%)

Age (y.o.)

 

64.7 ± 1.4

Height (cm)

 

160.6 ± 1.5

Body weight (kg)

 

66.5 ± 1.9

BMI

 

25.7 ± 0.7

Complication(s)

Retinopathy

0%

 

Nephropathy

2 (5.90%)

 

Neuropathy

0%

 

Hypertension

26 (76.5%)

 

Dyslipidemia

17 (50.0%)

 

CAD or CVD

11 (32.4%)

Drug(s)

ACEI/ARB

21 (61.8%)

 

Ca antagonist

24 (70.6%)

 

Diuretics

9 (26.5%)

 

HMG-CoA reductase

22 (64.7%)

  1. BMI: body mass index, CAD: coronary artery disease, CVD: cerebrovascular disease, ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin 2 receptor blocker, HMG-CoA reductase: hydroxymethylglutaryl-CoA reductase.